RecallDepth
Class II Terminated

Loxapine Capsules, USP 50 mg, packaged in 100 Unit Dose capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC 51079-903-20.

Company
Mylan Institutional, Inc. (D.B.A. Udl Laboratories)
Recall Initiated
May 1, 2018
Posted
May 30, 2018
Recall Number
D-0823-2018
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
1,152 blister cards of 100 capsules each
Firm Location
Rockford, IL, United States

Reason for Recall

GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination

Distribution

Nationwide in the U.S.

Lot / Code Info

Lot #: 3092310, Exp. 03/2019

More recalls by Mylan Institutional, Inc. (D.B.A. Udl Laboratories)

View all recalls by this company →

Other recent Class II Drug recalls